Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis

Inflammatory Bowel Diseases

Volumn 20, Issue 2, 2014, Pages 231-239

  Bouguen, Guillaume ^a,b   Levesque, Barrett G ^a   Pola, Suresh ^a   Evans, Elisabeth ^a   Sandborn, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Mucosal healing; Treat to target; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN;

ADULT; ARTICLE; BODY MASS; CLINICAL PRACTICE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; ENDOSCOPY; ERYTHROCYTE SEDIMENTATION RATE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEALING; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCOSAL HEALING; PRIORITY JOURNAL; PROBABILITY; PROCTITIS; SIGMOIDOSCOPY; SMOKING; ULCER HEALING; ULCERATIVE COLITIS; YOUNG ADULT; COLITIS, ULCERATIVE; COLONOSCOPY; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WOUND HEALING;

ADULT; COLITIS, ULCERATIVE; COLONOSCOPY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WOUND HEALING;

EID: 84893736515     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000437985.00190.aa     Document Type: Article

References (29)

1. Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012; 380:1606-1619.
2. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3-11.
3. Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut. 1990;31:329-333.
4. Hendriksen C, Kreiner S, Binder V. Long term prognosis in ulcerative colitis-based on results from a regional patient group from the county of Copenhagen. Gut. 1985;26:158-163.
5. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507-515.
6. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481-489.
7. Filippi J, Allen PB, Hébuterne X, et al. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Curr Drug Targets. 2011;12:1440-1447.
8. Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. [published online ahead of print September 10, 2013]. doi: 10. 1016/j.cgh.2013.09.006.
9. Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008;135:1442-1447.
10. Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422.
11. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:483-489.
12. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194-1201.
13. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7:15-29.
14. Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. [published online ahead of print August 1, 2013]. doi: 10.1016/j.cgh.2013.07. 022.
15. Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012;107:1684-1692.
16. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13-20.
17. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
18. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099-1105.
19. Laharie D, Filippi J, Roblin X, et al. Impact of mucosal healing on longterm outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther. 2013;37:998-1004.
20. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2: 219-225.
21. Panccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial. Gastroenterology. 2011;140:S134.
22. Feagan BG, Sandborn WJ, D'Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013;145:149-157.
23. Römkens TEH, Kampschreur MT, Drenth JPH, et al. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a metaanalysis of clinical trials. Inflamm Bowel Dis. 2012;18:2190-2198.
24. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
25. Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. [published online ahead of print July 12, 2013]. doi: 10.1016/j.cgh. 2013.06.019.
26. Nguyen GC, LaVeist TA, Harris ML, et al. Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1233-1239.
27. Ghosh S, D'Haens G, Feagan BG, et al. What do changes in inflammatory bowel disease management mean for our patients? J Crohns Colitis. 2012; 6:S243-S249.
28. Travis SPL, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535-542.
29. Lemmens B, Arijs I, Van Assche G, et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis. 2013;19:1194-1201.